Shandong Ruifeng Chemical Co., Ltd. Overview
Two similarly named listed companies should not be confused with it. 瑞丰新材 (300910.SZ), Xinxiang Richful Lube Additive, makes lubricant additives. 瑞丰转债 (123126) is this company's own convertible bond, which has now been redeemed.
Shandong Ruifeng is one of China's leading producers of PVC processing and impact-modifying additives. It has about 200,000 t/yr of combined capacity across ACR acrylic processing aids and impact modifiers, MBS impact modifiers and MC impact modifiers. The company describes itself as the leader in domestic ACR and MBS, supplying close to 3,000 domestic customers and exporting to more than 60 countries under the "LUSHAN" brand. Earnings are thin and cyclical: net margin was 1.1%–5.0% over FY2021–FY2025, because the business is exposed to acrylate, butadiene and styrene costs and to PVC demand tied to construction. Management is reshaping the company into a broader "new materials" platform:
-
higher-margin engineering-plastic additives and core-shell rubber (CSR) tougheners aimed at replacing imports;
-
a 60 kt/yr PBAT biodegradables line being retrofitted for PETG/PCTG specialty polyester;
-
early-stage black phosphorus anode material, SBR battery binder and dextran;
-
since September 2026, a proposed CNY 499M controlling acquisition of loss-making electronic-resin maker Anhui Mituo, which would take it into copper-clad laminate (CCL) materials.
H1 2026 profits rose sharply year on year, and the share price has nearly doubled in 2026.
Company's own description
In its FY2024 annual report summary, the company describes its core business as plastic additives in two lines.
General-purpose plastic (PVC) additives: The main products are ACR processing aids and impact modifiers, MBS impact modifiers and MC impact modifiers, with combined capacity of nearly 200,000 tonnes. Each product family has its own end uses:
-
ACR goes into PVC pipes, profiles, WPC and SPC flooring, wall panels, transparent sheet and foam board.
-
MBS goes into transparent PVC sheet (pharmaceutical and consumer packaging), pipes, magnetic-card materials and functional films.
-
MC goes into wire and cable, hoses, tapes, rubber sheet and PVC profile/pipe modification.
Engineering-plastic additives: The main products are PC/ABS toughening modifiers, ABS high-rubber powder and ASA rubber powder. The company states that domestic supply of these grades has historically been imported, mainly from Kaneka (Japan), Dow (US) and LG (Korea), and that its products have reached volume sales.
The same report says the company has 60,000 t/yr of PBAT biodegradable polymer capacity.
In a June 2025 institutional site-visit record, management organised the business into four segments: plastic-additive materials, polyester materials, new-energy materials and synthetic-biology materials. Tianfeng Securities (July 2026) describes the structure as "PVC additives + engineering-plastic additives + synthetic-biology materials + new materials". MarketScreener's summary of the filings describes three businesses: plastic additives; biodegradable materials (PBAT); and a "new product" business covering special polyester, synthetic biomaterials, battery binders and black phosphorus.
Independent characterisation
Ruifeng is best understood as a mid-cap commodity-to-specialty intermediate chemical producer. More than 90% of revenue still comes from a single mature product family, PVC additives. Revenue is almost entirely product sales: tonnage-based, priced off raw-material costs, and with no meaningful service, subscription or licensing income. S&P data show "other revenue" of only CNY 2–7M a year.
Value-chain position. Ruifeng buys monomers and polymers, including methyl acrylate, butyl acrylate, butadiene, styrene and HDPE, and polymerises them into core-shell or chlorinated polymer additives. Compounders and converters use these at 1–10 phr loadings in PVC and engineering-plastic processing. The additive is a small share of the customer's bill of materials but critical to performance, such as impact strength, melt processing and transparency. That gives Ruifeng moderate pricing power in normal markets. Tianfeng notes the company reprices flexibly in line with raw materials, but price competition intensifies in downturns: management cut prices in Q1 2025 to defend market share.
Customer types. PVC pipe, profile, flooring and sheet extruders (heavily tied to construction and real estate); packaging film and pharmaceutical blister-sheet producers; card makers; ABS/ASA and PC/ABS compounders serving automotive and electronics; and, in development, lithium-ion battery cell makers (SBR binder) and CCL laminators (CSR, and electronic resins through the Mituo deal).
End-market exposure. Construction and building materials are the largest exposure through PVC pipes, profiles and flooring. Packaging, consumer goods, automotive, electrical/electronics, agriculture and disposable packaging (PBAT mulch films and bags), and new energy and electronics (developing) make up the rest. Management has said it is deliberately shifting PVC-additive sales toward non-property uses such as sheet, cards, packaging film and pharmaceutical packaging to offset the property cycle (H1 2026 commentary).
Revenue model mix. About 100% product sales. Service, subscription and licensing revenue are not publicly disclosed and are assessed as immaterial.
Strategy
Stated strategy
Management has stated its themes consistently across the FY2024 annual report, the 2025 results briefings and the 2026 investor Q&A:
-
Pursue "transformation and upgrading" (转型升级) while staying focused on the core business.
-
Concentrate on the new-materials industry.
-
Move plastic additives toward high-end, fine-chemical grades, replacing imports from Japanese, Korean, US and European incumbents.
-
Cultivate new growth points in polyester, new-energy and synthetic-biology materials.
Since August 2026 the company has added an explicit ambition to enter the CCL and electronic-resin value chain.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Detail | Targets / status |
|---|---|---|
| Engineering-plastic additive expansion | 60 kt/yr new capacity: Phase 1 of 20 kt (including 5 kt CSR) under construction; Phase 2 of 40 kt (including 5 kt CSR) | Phase 1 start-up end-2026; Phase 2 to start in 2027 |
| Import-substitution grades | Transparent ABS toughener (in mass production); PMMA toughener, CSR, silicone-acrylic modifiers (small-batch or pilot) | Batch production 2026–2027 |
| PBAT line retrofit to PETG/PCTG | Lets the 60 kt/yr line co-produce specialty copolyesters | First targeted for 2H2025 |
| Black phosphorus industrialisation | Tonne-scale pilot built (Ruifeng Yueneng) | Trial production; partnerships with downstream firms and research institutes |
| SBR battery binder | Multiple grades; IATF 16949 certified; sampling with top cell makers | Customer qualification |
| Dextran | Veterinary iron-dextran precursor | Small-batch sales; expand capacity "as appropriate" |
| PVC-additive end-market rebalancing | Push into sheet, card, packaging film and pharmaceutical packaging to reduce property-cycle exposure | H1 2026 volume and margin up |
| Digital manufacturing | Shandong Provincial Smart Factory designation | Achieved Jul 2025 |
| Capital structure | Downward revision of conversion price (Dec 2024), then forced conversion and redemption of the bond (Jun 2026) | Leverage materially reduced |
| Electronic-chemicals entry (Anhui Mituo) | CNY 499M for 68.065% | Pending EGM; see Section 11 |
| Dividend policy | Cash dividends maintained even in the weak FY2024 (CNY 0.05/share) | FY2025 dividend approved May 2026 |
Medium-term guidance
| Metric | FY2026E | FY2027E | FY2028E |
|---|---|---|---|
| Revenue (CNY M, Tianfeng estimate) | 2,204 | 2,647 | 3,138 |
| Revenue growth (%, Tianfeng estimate) | 11.96 | 20.06 | 18.58 |
| Net income to shareholders (CNY M, Tianfeng estimate) | 126 | 200 | 316 |
| EPS (CNY, Tianfeng estimate) | 0.45 | 0.72 | 1.13 |
The company has not published quantitative medium-term financial targets; no numeric revenue or margin guidance was identified. The only sell-side forecast found is from Tianfeng Securities (initiation, 13 Jul 2026):
These forecasts predate the Mituo deal.
Products & Services
PVC additives (LUSHAN brand)
| Product | Description and function | Key applications | Target customer | Status / capacity |
|---|---|---|---|---|
| ACR processing aids | Acrylic (PMMA-based) copolymers that speed PVC fusion, improve melt strength and surface finish | PVC pipes, profiles, sheet, foam products | PVC extruders | Core; part of 100 kt/yr ACR capacity |
| ACR impact modifiers | Acrylic core-shell impact modifiers that give weather-resistant toughness | Window and door profiles, pipes, fittings, WPC/SPC flooring, wall panels | Profile and flooring makers | Core. The company claims to be China's largest ACR producer. |
| Medium/ultra-high-MW acrylic processing aids (foam regulators) | High-molecular-weight ACR for cell-structure control in foamed PVC | PVC foam board, foam pipes, WPC | Foam-board and WPC makers | Flagship differentiated grade (cited by Morningstar) |
| MBS impact modifiers | Methyl methacrylate-butadiene-styrene core-shell modifier; transparent impact modification | Transparent PVC sheet (pharmaceutical blisters, consumer packaging), pipes, magnetic and smart cards, functional films | Sheet and card makers | 60 kt/yr. Described as a domestic leader with over 20 years of MBS experience. |
| MC impact modifiers | Chlorinated-polyolefin type modifier (closely related to CPE) | Wire and cable, hoses, tapes, rubber sheet, PVC profile/pipe modification | Cable and rubber compounders | 40 kt/yr |
| CPE-135A | Chlorinated polyethylene impact modifier | PVC profiles and pipes | PVC processors | Listed in third-party catalogues; may overlap with the MC line |
| Methyl tin mercaptide | Organotin heat stabiliser | Transparent and rigid PVC | PVC processors | Listed on the company store / Knowde; scale not disclosed |
| PVC lubricants / lubricating processing aids | Internal and external lubricants | Rigid PVC | PVC processors | Listed; scale not disclosed |
| Epoxidised soybean oil | Bio-based secondary plasticiser and co-stabiliser | Flexible PVC | PVC processors | Listed; scale not disclosed |
Pricing model: spot and contract tonnage pricing, adjusted to raw-material costs. FY2025 average realised price was about CNY 11,576/t (Tianfeng). List prices are not disclosed.
Engineering-plastic additives
| Product | Description | Applications | Competing incumbents (per company) | Status |
|---|---|---|---|---|
| PC/ABS toughening modifier | Core-shell impact modifier for PC and PC/ABS alloys | Automotive, electronics | Kaneka, Dow, LG Chem | Volume sales |
| ABS high-rubber powder | Grafted polybutadiene rubber powder blended with SAN to make ABS | Automotive, appliances, electrical, building | Kumho, BASF (high-end grades) | Volume sales |
| ASA rubber powder | Acrylate-rubber terpolymer blended with SAN to make weather-resistant ASA | Outdoor and automotive exterior, building | Imports | Volume sales |
| Transparent ABS toughener | Transparent-grade core-shell modifier | Consumer electronics, housings | Imports | Mass production and shipments began in 2026 |
| PMMA toughener | Impact modifier for acrylic sheet | Lighting, displays | Imports | Small-batch sales |
| Silicone-acrylic impact modifier | Low-temperature toughening | Automotive, electronics | Imports | Pilot or scale-up done; batch production planned 2026–27 |
| CSR (core-shell rubber) epoxy toughener | Toughener for epoxy systems | CCLs including for AI servers, adhesives, composites | Kaneka (benchmarked high-end grades) | Small-batch from pilot line. 5 kt/yr in Phase 1 (end-2026) and 5 kt/yr in Phase 2. |
Capacity: 10 kt/yr existing, running at full utilisation. A 60 kt/yr project is planned: Phase 1 of 20 kt/yr (including 5 kt CSR) targeted to start up by end-2026, and Phase 2 of 40 kt/yr (including 5 kt CSR) to start "at an appropriate time" in 2027. Average price in FY2025 was about CNY 16,093/t.
Polyester materials
| Product | Description | Applications | Status |
|---|---|---|---|
| PBAT | Biodegradable aliphatic-aromatic copolyester | Agricultural mulch film, shopping bags, disposable packaging | 60 kt/yr line; batch sales achieved. The line did not run normally in FY2024 and was impaired by CNY 12.30M. |
| PBS | Biodegradable polyester | Packaging | Part of the polyester platform; scale not disclosed |
| PLA (resale/compounds) | Polylactic acid | Compostable products | Listed by third-party profile (roic.ai) |
| PETG / PCTG | Glycol-modified copolyesters | Cosmetics and personal-care packaging, appliances, sheet and film, medical devices, 3D printing | Pilot complete. The PBAT line is being retrofitted for co-production; management first targeted 2H2025 for normal running. |
New-energy materials
| Product | Description | Status |
|---|---|---|
| Black phosphorus (Ruifeng Yueneng, controlled subsidiary) | Layered phosphorus allotrope with high theoretical capacity and conductivity, targeted at fast-charge and solid-state anodes | 100 kg-scale unit ran normally in 2024. A tonne-scale pilot is built and in trial production, with application partnerships being pursued. No commercial revenue disclosed. |
| SBR lithium-ion battery binder | Styrene-butadiene rubber binder for graphite anodes, building on MBS emulsion know-how | Several grades launched; IATF 16949 certified; samples with multiple leading cell makers. Management said in May 2024 that no supply relationship had yet been established. |
Synthetic-biology materials
| Product | Description | Status |
|---|---|---|
| Dextran (Ruifeng Bio subsidiary) | Polysaccharide used to make iron dextran, an injectable veterinary iron supplement | Small-batch sales; capacity to expand depending on market development |
Other chemicals
| Product | Note |
|---|---|
| Epichlorohydrin (ECH) | Listed by Simply Wall St and Investing.com. Management says ECH is a raw material for Anhui Mituo's epoxy resins, which is one stated synergy of the acquisition. Volume not disclosed. |
Financial Narrative
Source: S&P Global Market Intelligence, normalised from CAS filings (via StockAnalysis.com, last updated Jul 2026). Key lines were cross-checked against the FY2024 annual report summary: revenue CNY 2,000.79M; net profit to shareholders CNY 22.08M; recurring (non-GAAP-equivalent "扣非") net profit CNY 18.42M; operating cash flow −CNY 23.20M; weighted ROE 1.92%. All values are in CNY millions unless labelled.
Income statement
Revenue CAGR FY2021–FY2025: about 1.5% a year (derived: (1969/1858)^(1/4) − 1).
Interim and quarterly data
Source: FY2024 annual report summary. The Q4 2024 loss reflects the PBAT impairment and year-end charges.
H1 2026 (company report, 27 Jul 2026):
-
Revenue CNY 1,097M (+9.04%); net profit CNY 58.94M (+348.43%); basic EPS CNY 0.23.
-
Gross margin 18.86%; net margin 5.35%.
-
Q2 2026: revenue CNY 575M (+8.07%) and net profit CNY 38.70M (+392.42%). Q1 2026 net profit was CNY 20.24M (+282.99%).
-
Operating cash flow per share was only about CNY 0.02, roughly CNY 6.23M in total.
-
On S&P TTM data to June 2026: revenue CNY 2,060M, EBITDA CNY 213.57M, net income CNY 76.13M, gross margin 17.12%.
Balance sheet
30 June 2026 (S&P): total debt fell to CNY 570.44M after the bond converted to equity. Long-term debt is now only CNY 19.60M; short-term debt is CNY 545.18M plus CNY 5.15M current portion of LTD. Net debt is CNY 288.07M, equity CNY 1,548M and book value per share CNY 5.54. Paid-in capital rose by about CNY 406M as bonds converted.
Cash flow
Note on buybacks: no buyback programme was identified in this research. S&P's FY2021 "issuance of common stock" of CNY 340M is the convertible bond proceeds as classified by S&P, and FY2023's CNY 123.6M includes the controller placement.
Ratios
Ratios are derived from the S&P data above unless marked as reported. ROE uses year-end equity except for the company-reported weighted ROE rows. ROIC is computed as EBIT × (1 − effective tax rate) / (total debt + equity).
Stockstar, citing historical annual data, gives ROIC of 3.36% for FY2025 and about 3% for FY2024, with a 10-year median of 6.74%. This is consistent with the computed series.
TTM to June 2026 (derived): net debt to EBITDA 1.35x; EBIT interest coverage 3.22x; debt to equity 0.37x.
Commentary
Revenue. Revenue has been flat at roughly CNY 1.8–2.0bn since FY2021. The 42.75% jump in FY2021 reflected raw-material pass-through as acrylate and butadiene prices spiked. FY2024's 12.66% rise came from volume, as the company traded price for share. The FY2025 decline of 1.59% came despite 7.6% higher PVC-additive volumes, meaning realised prices fell. The FY2021–25 CAGR of about 1.5% confirms a mature core business.
Margins. Gross margin compressed from 18.4% (FY2021) to 14.1% (FY2024) because:
-
raw-material volatility outran price pass-through;
-
the company cut prices deliberately to hold share (Q1 2025 management commentary);
-
the idle PBAT asset added fixed cost.
The inflection came in H1 2026, when gross margin reached 18.86%. Methyl acrylate costs fell about 10% while butadiene and styrene rose 14% and 7% (Tianfeng, YTD to 3 Jul 2026), and management pushed through broad price increases. A richer engineering-additive mix also helped.
PBAT drag. The PBAT project explains most of the FY2024 collapse. Management quantified the hit at nearly CNY 64M: depreciation and bond-interest amortisation of CNY 39.88M plus CNY 12.30M of impairment and other items. D&A rose from CNY 57.8M to CNY 92.8M and interest expense nearly doubled to CNY 41.8M. Because the bond's effective-interest amortisation stopped after the June 2026 conversion and redemption, about CNY 20M+ a year of non-cash financing cost should fall away from 2H2026. This is a key mechanical earnings tailwind.
Cash flow. Cumulative free cash flow over FY2021–FY2024 was about −CNY 495M. It was funded by the CNY 340M convertible bond, the CNY 105M placement and rising bank debt. FY2025 was the first meaningfully positive FCF year (CNY 99.4M), as capex fell to CNY 33.7M and inventory was released.
Working capital. This is a structural weakness. Receivables days rose from about 89 to about 124 over five years, and the cash conversion cycle rose from about 85 to about 155 days. H1 2026 operating cash flow of only about CNY 6M, against CNY 59M net profit, shows the issue persisting. This matters now because up to CNY 350M of the Mituo price is to be financed with acquisition loans.
Balance sheet. Before conversion, leverage of 3.5–3.8x net debt to EBITDA was high for a cyclical business. The bond conversion transformed the balance sheet: equity rose to CNY 1.55bn and net debt fell to CNY 288M. That headroom is being redeployed into the Mituo acquisition, which pro forma would add up to CNY 350M of new debt plus Mituo's own net liabilities (CNY 434M of liabilities at 30 Jun 2026).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment (Management Definition) Overview
| Segment (management definition) | Contents | Status |
|---|---|---|
Plastic-additive materials: PVC additives | ACR processing aids and impact modifiers (100 kt/yr); MBS impact modifiers (60 kt/yr); MC impact modifiers (40 kt/yr). Third-party profiles also list CPE-135A, methyl tin mercaptide, PVC lubricants, epoxidised soybean oil and ultra-high-molecular-weight processing aids. | Core; over 90% of revenue |
Plastic-additive materials: engineering-plastic additives | PC/ABS toughening modifiers, ABS high-rubber powder, ASA rubber powder, transparent ABS toughener, PMMA toughener, silicone-acrylic impact modifiers, CSR (core-shell rubber) epoxy toughener | Fast-growing; 10 kt/yr running at full utilisation; 60 kt/yr expansion under way |
Polyester materials | PBAT/PBS biodegradables (60 kt/yr line); PETG/PCTG specialty copolyester (pilot complete; retrofit of PBAT line) | Under-utilised; impaired in FY2024 |
New-energy materials | Black phosphorus anode material (subsidiary Ruifeng Yueneng 瑞丰玥能); SBR lithium-ion battery binder | Pilot and qualification stage |
Synthetic-biology materials | Dextran, used for iron-dextran veterinary iron supplements (subsidiary Ruifeng Bio 瑞丰生物) | Small-batch sales |
Proposed: electronic chemicals | Electronic-grade epoxy, low-dielectric resins (PPO, BMI, hydrocarbon), photo-initiators, via Anhui Mituo (68.065%) | Pending shareholder approval |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (CNY Mn, reported) | 1,776 | 2,001 | 1,969 |
PVC additives revenue (CNY Mn; FY2023 and FY2025 derived) | 1,732 | 1,888 | 1,817 |
Engineering-plastic additives revenue (CNY Mn; FY2023 derived) | 34 | 107 | 147 |
PVC additives share of total revenue (%) | 97.5 | 94.4 | 92.3 |
Engineering-plastic additives share of total revenue (%) | 1.9 | 5.3 | 7.5 |
PVC additives revenue growth YoY (%) | — | 9.0 | -3.8 |
Engineering-plastic additives revenue growth YoY (%) | — | 212.5 | 37.8 |
Engineering-plastic additives gross margin (%; FY2024 derived) | — | 23.6 | 25.8 |
PVC additives sales volume (kt; FY2024 derived) | — | 145.9 | 157.0 |
Engineering-plastic additives production volume (kt; FY2024 derived) | — | 6.5 | 10.0 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 1,858 | 1,832 | 1,776 | 2,001 | 1,969 |
Revenue growth YoY (%) | 42.75 | -1.45 | -3.03 | 12.66 | -1.59 |
Cost of revenue (CNY Mn) | 1,517 | 1,537 | 1,468 | 1,719 | 1,682 |
Gross profit (CNY Mn) | 341.48 | 294.44 | 308.24 | 282.03 | 286.80 |
SG&A (CNY Mn) | 182.22 | 209.92 | 187.34 | 186.03 | 204.23 |
R&D (CNY Mn, S&P normalised) | 4.31 | 6.43 | 14.60 | 9.01 | 8.57 |
Operating income / EBIT (CNY Mn) | 148.36 | 71.26 | 105.63 | 77.47 | 76.49 |
D&A (CNY Mn) | 40.67 | 53.28 | 57.82 | 92.84 | 95.15 |
EBITDA (CNY Mn) | 189.04 | 124.54 | 163.45 | 170.31 | 171.63 |
Interest expense (CNY Mn) | 20.71 | 21.23 | 22.58 | 41.78 | 44.00 |
Pre-tax income (CNY Mn) | 106.53 | 71.98 | 89.99 | 32.27 | 33.29 |
Income tax (CNY Mn) | 15.49 | 10.84 | 4.71 | 10.56 | 3.53 |
Net income to shareholders (CNY Mn) | 92.87 | 61.14 | 85.29 | 22.08 | 30.33 |
Recurring net income ex non-recurring items (CNY Mn) | — | 47.03 | 81.87 | 18.42 | — |
EPS basic (CNY) | 0.40 | 0.26 | 0.36 | 0.10 | 0.13 |
EPS diluted (CNY) | 0.39 | 0.26 | 0.36 | 0.10 | 0.13 |
Dividend per share declared for fiscal year (CNY, S&P) | 0.12 | 0 | 0.10 | 0.05 | 0.10 |
Gross margin (%) | 18.38 | 16.08 | 17.36 | 14.10 | 14.57 |
Operating margin (%) | 7.98 | 3.89 | 5.95 | 3.87 | 3.89 |
EBITDA margin (%) | 10.17 | 6.80 | 9.20 | 8.51 | 8.72 |
Net margin (%) | 5.00 | 3.34 | 4.80 | 1.10 | 1.54 |
Effective tax rate (%) | 14.54 | 15.06 | 5.24 | 32.70 | 10.60 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 |
|---|---|---|---|---|
Revenue (CNY Mn) | 488.07 | 492.22 | 489.71 | 530.78 |
Net income to shareholders (CNY Mn) | 9.78 | 13.00 | 13.79 | -14.49 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (CNY Mn) | 1,688 | 1,942 | 2,174 | 2,273 | 2,311 |
Cash and equivalents (CNY Mn) | 233.33 | 186.05 | 305.81 | 280.06 | 358.67 |
Accounts receivable incl. notes (CNY Mn) | 452.06 | 509.27 | 525.82 | 614.54 | 669.38 |
Inventory (CNY Mn) | 118.58 | 203.10 | 217.16 | 321.45 | 272.01 |
PP&E (CNY Mn) | 647.01 | 811.45 | 900.54 | 861.23 | 797.55 |
Construction in progress (CNY Mn) | 221.96 | 336.65 | 51.49 | 44.22 | 40.00 |
Goodwill (CNY Mn) | 0 | 0 | 0 | 0 | 0 |
Other intangible assets (CNY Mn) | 75.69 | 99.42 | 96.62 | 93.82 | 98.26 |
Short-term debt incl. current portion of LTD (CNY Mn) | 185.98 | 383.75 | 363.42 | 491.51 | 546.20 |
Long-term debt incl. convertible bond (CNY Mn) | 385.76 | 374.56 | 425.49 | 441.62 | 423.10 |
Total debt (CNY Mn) | 571.74 | 758.31 | 789.43 | 933.39 | 969.30 |
Net debt (CNY Mn) | 338.41 | 572.26 | 483.62 | 653.34 | 610.63 |
Shareholders' equity (CNY Mn) | 894.04 | 935.49 | 1,141 | 1,125 | 1,142 |
Working capital (CNY Mn) | 474.61 | 324.71 | 505.82 | 553.49 | 599.61 |
Book value per share (CNY) | 3.85 | 4.03 | 4.56 | 4.49 | 4.56 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (CNY Mn) | 111.14 | -8.62 | 96.20 | -23.20 | 133.04 |
Capital expenditure (CNY Mn) | 271.58 | 176.31 | 153.30 | 69.30 | 33.67 |
Free cash flow (CNY Mn) | -160.44 | -184.93 | -57.10 | -92.50 | 99.37 |
Change in working capital (CNY Mn) | -43.87 | -147.13 | -67.71 | -196.04 | -33.20 |
Cash dividends paid (CNY Mn) | 39.99 | 37.11 | 8.50 | 38.49 | 30.88 |
Equity issued (CNY Mn) | 340.00 | 0 | 123.60 | 0 | 0 |
Net debt issued/repaid (CNY Mn) | -75.95 | 178.80 | 167.73 | 197.03 | 181.00 |
Share buybacks (CNY Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE on year-end equity (%) | 10.39 | 6.54 | 7.47 | 1.96 | 2.66 |
ROE weighted, company reported (%) | — | 6.70 | 8.63 | 1.92 | — |
ROA on year-end assets (%) | 5.50 | 3.15 | 3.92 | 0.97 | 1.31 |
ROIC computed (%) | 8.65 | 3.58 | 5.19 | 2.53 | 3.24 |
Current ratio (x) | 2.19 | 1.52 | 1.84 | 1.79 | 1.81 |
Debt to equity (x) | 0.64 | 0.81 | 0.69 | 0.83 | 0.85 |
Net debt to EBITDA (x) | 1.79 | 4.59 | 2.96 | 3.84 | 3.56 |
Interest coverage, EBIT / interest (x) | 7.16 | 3.36 | 4.68 | 1.85 | 1.74 |
Asset turnover (x) | 1.10 | 0.94 | 0.82 | 0.88 | 0.85 |
Days sales outstanding | 89 | 101 | 108 | 112 | 124 |
Days inventory outstanding | 29 | 48 | 54 | 68 | 59 |
Days payables outstanding | 32 | 33 | 35 | 26 | 28 |
Cash conversion cycle (days) | 85 | 117 | 127 | 154 | 155 |
Revenue by Region and Revenue by Region (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (CNY Mn) | 1,776 | 2,001 | 1,969 |
United States share of total revenue (%) | — | 0.49 | — |
Valuation Snapshot
| Metric | Value | Date / source |
|---|---|---|
Last close | CNY 20.38 | 30 Sep 2026 (StockAnalysis) |
Recent pre-rally price | CNY 10.69 | Dec 2025 (Simply Wall St) |
Approximate year-to-date change | About +90% (derived: 20.38 / 10.69) | — |
52-week low / high | CNY 9.75 / 24.18 | MarketScreener (Sep 2026) |
3-year and 5-year low | CNY 5.12 | MarketScreener |
Free float | About 58.8% | MarketScreener |
Valuation Multiples
| Multiple | Ruifeng | Note |
|---|---|---|
Market cap | About CNY 5,697M | Derived |
Enterprise value | About CNY 5,985M | Derived |
P/E (TTM EPS CNY 0.33) | About 62x | Derived |
P/E FY2026E (Tianfeng EPS CNY 0.45) | About 45x | Derived |
P/E FY2027E (Tianfeng EPS CNY 0.72) | About 28x | Derived |
EV/EBITDA (TTM EBITDA CNY 213.6M) | About 28x | Derived |
EV/Sales (TTM revenue CNY 2,060M) | About 2.9x | Derived |
P/B (BVPS CNY 5.54) | About 3.7x | Derived |
Peer reference | Tianfeng comparables (Chenghe, Jianbang, Shengquan) average 2027 P/E of 30.73x | Tianfeng, Jul 2026 |
Analyst Ratings & Targets
| Broker | Date | Rating | Target price | Note |
|---|---|---|---|---|
Tianfeng Securities | 13 Jul 2026 | Buy (initiation) | CNY 21.98 | Based on 30.73x 2027E P/E |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
DPS declared for fiscal year (CNY, S&P) | 0.12 | 0 | 0.10 | 0.05 | 0.10 |
Cash dividends paid in year (CNY Mn) | 39.99 | 37.11 | 8.50 | 38.49 | 30.88 |
Payout ratio of net income (%; derived from declared DPS × basic shares) | 30.0 | 0 | 27.8 | 50.0 | 76.8 |
Capital Markets
| Item | Detail |
|---|---|
International credit ratings (Moody's, S&P, Fitch) | None; unrated |
Debt maturity profile, 30 Jun 2026 | Short-term borrowings CNY 545.18M; current portion of long-term debt CNY 5.15M; long-term debt CNY 19.60M; leases about CNY 0.5M. About 97% of debt matures within one year (rolling bank facilities). |
Pending new debt | Up to CNY 350M of M&A loans for Mituo |
Analyst Conclusions
Guidance and expectations
Management gives no quantitative guidance. Qualitatively it expects:
-
seasonal recovery in PVC demand in Q3 (PVC prices rebounded from July 2026);
-
Phase 1 of the engineering-additive expansion (20 kt/yr including 5 kt CSR) by end-2026;
-
continued ramp-up of new grades through 2026–27;
-
gradual volume build at Mituo from 2H2026 into 2027, with no near-term profit expected from the target.
Tianfeng's forecasts, the only ones found, are revenue of CNY 2.20bn / 2.65bn / 3.14bn and net profit of CNY 126M / 200M / 316M for FY2026–FY2028. Annualised H1 2026 net profit of about CNY 118M makes the FY2026 figure plausible, before Mituo consolidation losses.
Bull case
-
Operating leverage on recovery. Gross margin rose from 14.6% (FY2025) to 18.9% (H1 2026). Every percentage point of gross margin on about CNY 2.1bn of revenue is worth about CNY 21M of pre-tax profit, against a FY2025 net-profit base of only CNY 30M.
-
Mix shift plus capacity. Engineering-plastic additives grow from 10 to 30 kt/yr effective capacity by 2027 at a roughly 39% price premium and a 25.8% gross margin. Substituting Kaneka-grade CSR and toughener imports in AI-server CCLs could lift group margin structurally.
-
Cleaner balance sheet and cost relief. Bond conversion removed about CNY 400M of debt and about CNY 20M+ a year of interest amortisation. Net debt to EBITDA fell to 1.35x, creating capacity to fund growth.
Bear case
-
Value-destructive M&A. CNY 499M (about 9% of current market cap) for a target with CNY 41M of revenue and a CNY 62.5M loss, at 5.5x book, financed with up to CNY 350M of loans. The 2027 commitment is a loss, and the reported compensation cap covers under 9% of the commitment. Consolidating Mituo could erase a large part of 2027 earnings growth.
-
History of failed diversification. The PBAT plant (CNY 263M of bond proceeds) was idle and impaired, the PETG retrofit timing has slipped, SBR has no supply contracts, and black phosphorus is still in trial production.
-
Cyclical, cash-poor core. A cash conversion cycle of about 155 days, H1 2026 operating cash flow of about CNY 6M, and a PVC market described as in post-peak structural adjustment. A raw-material spike (butadiene +14% YTD) or property weakness could quickly reverse margin gains. A valuation of about 62x trailing P/E leaves no room for error.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing |
|---|---|
| EGM vote on the Mituo acquisition and loan financing | Oct–Nov 2026 |
| Q3 2026 report (margins, operating cash flow, receivables) | By 31 Oct 2026 |
| Start-up of Phase 1 engineering-additive capacity (20 kt including 5 kt CSR) | End-2026 |
| FY2026 annual report; any PBAT/PETG impairment; Mituo consolidation effect | Apr 2027 |
| PETG/PCTG commercial production status | Ongoing |
| SBR binder supply contract or black phosphorus commercial orders | Ongoing |
| Raw-material spreads (MMA/MA, butadiene, styrene) and PVC price trend | Monthly |
| Short-term debt refinancing and new M&A borrowing | Ongoing |
| Further broker initiations and FY2026 dividend | 2026–27 |
Analyst verdict
Shandong Ruifeng Chemical is a credible domestic leader in a mature, low-margin niche that is trying to buy and build its way into higher-value materials. The 2026 recovery is real. H1 net profit more than quadrupled, gross margin returned to about 19%, and the June 2026 forced conversion of its convertible bond cut net debt to under CNY 300M, removing the main mechanical drag that crushed FY2024 earnings. The most convincing growth engine is organic: the engineering-plastic additives business. It has grown at 38–42% a year, earns about 26% gross margin, is capacity-constrained at 10 kt/yr, and has a funded six-fold expansion whose first phase lands at end-2026. Core-shell polymer know-how built over 20 years in MBS is a genuine, transferable capability, and CSR tougheners for AI-server laminates give it a credible import-substitution story.
The investment case is now complicated by capital allocation. The CNY 499M Mituo acquisition was struck at about 5.5x book for a company losing more than its revenue and dependent on a handful of customers. Its debt funding re-levers a balance sheet that was only just repaired, and the weak protection in the earn-out recalls the PBAT episode, where CNY 263M of capital produced an idle, impaired plant. Cash conversion remains the chronic weakness: receivables keep lengthening, and H1 2026 operating cash flow was negligible against reported profit.
At about 62x trailing and about 45x FY2026E earnings (on Tianfeng's estimates), after a near-doubling of the share price, the market is already paying for successful execution of both the organic expansion and the Mituo turnaround. Our assessment is constructive on operations but cautious on valuation and governance: fundamentally attractive only if Q3–Q4 2026 confirm margins above 17% with positive operating cash flow, and if the Mituo terms are approved with tighter protection or a smaller cash commitment. Investors should treat the EGM vote and the Q3 cash-flow print as decisive near-term tests.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / notes | Age (source) |
|---|---|---|---|
Zhou Shibin (周仕斌) | Chairman; controlling shareholder and actual controller | Director since 2009 conversion; MarketScreener lists chairman since 1 Sep 2009. Signs the annual report as legal representative. | 61 (Investing.com); 64 (MarketScreener, later) |
Liu Chunxin (刘春信) | General Manager (CEO) and Director | GM since 2016 (Investing.com); MarketScreener's CEO entry starts 6 Jul 2017 | 47 to 50 |
Xu Yueling (许曰玲) | CFO (Head of Finance) | MarketScreener: since 1 Jan 2010 | 54 |
Zhao Ziyang (赵子阳) | Board Secretary | IR lead in 2025–26 records | — |
Song Zhigang (宋志刚) | Deputy GM and Director | Since 2016 (Investing.com) | 56 |
Tang Chuanxun (唐传训) | Director | Since 2009 | 49 |
Wang Jian (王健) | Director; concert party of the controller | Since 2021 (Investing.com) | 37 |
Shao Zeheng (邵泽恒) | Director | Investing.com | 41 |
Xu Suxian (许肃贤) | Independent Director | Attended May 2025 results briefing | — |
Wang Xiaodong | Independent Director (per Investing.com; may be legacy) | — | 56 |
Dong Hua | Independent Director (per Investing.com; may be legacy) | — | 46 |
Zheng Kai | Independent Director (per Investing.com; may be legacy) | — | 71 |
Xu Yingjie (徐颖杰) | Head of accounting function | Co-signs FY2024 financial statements | — |
Zhu Xihai (朱西海) | Securities Affairs Representative | IR record, Jun 2025 | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Shares (M) | % of float | Change in H1 2026 | Type |
|---|---|---|---|---|
Zhou Shibin (controller) | 16.85 tradable | 7.53 | Unchanged | Individual (total holdings including restricted shares are higher) |
Sang Peizhou (桑培洲) | 9.398 | 4.20 | −22.55% | Individual (historic #2 holder) |
Chen Qiang (陈强) | 3.199 | 1.43 | New | Individual |
Wu Jianning (伍建宁) | 3.10 | 1.39 | −0.96% | Individual |
Wei Guiying (魏贵英) | 2.784 | 1.24 | +16.99% | Individual |
Cai Zhixing (蔡志兴) | 2.754 | 1.23 | +0.71% | Individual |
Chen Wenjian (陈文健) | 2.658 | 1.19 | Unchanged | Individual |
Wang Gongjun (王功军) | 2.646 | 1.18 | −17.38% | Individual |
Zhou Xiaoyuan (周晓渊) | 1.669 | 0.75 | New | Individual |
Wang Hongtao (王洪涛) | 1.38 | 0.62 | Unchanged | Individual |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Country | Relevant products | Relative positioning vs Ruifeng |
|---|---|---|---|---|
PVC additives (ACR/MBS) | Kaneka Corporation | Japan | Kane Ace MBS/ACR, MX core-shell modifiers | Global technology leader and premium brand; much larger and diversified |
PVC additives | Dow Inc. | US | Paraloid acrylic and MBS modifiers | Global leader; premium grades |
PVC additives | Arkema | France | Durastrength, Plastistrength, Clearstrength | Global premium; strong in Europe and the Americas |
PVC additives | Mitsubishi Chemical Group | Japan | Metablen modifiers | Premium Asian competitor |
PVC additives / ABS powder | LG Chem | Korea | MBS, ABS high-rubber powder | Strong in Asia; integrated with ABS |
PVC additives (domestic) | Shandong Rike Chemical (日科化学, 300214.SZ) | China | ACR, CPE, rubber-plastic modifiers | — |
PVC additives (CPE/MC, domestic) | Weifang Yaxing Chemical (亚星化学, 600319.SH) | China | CPE | CPE specialist |
Engineering-plastic additives | Kumho Petrochemical | Korea | ABS high-rubber powder | Incumbent in high-end ABS powder |
Engineering-plastic additives | BASF | Germany | ABS/ASA rubber powders and modifiers | Incumbent in high-end grades |
Polymer additives (Tianfeng comparables) | Chenghe Technology (呈和科技), Jianbang (键邦股份), Shengquan Group (圣泉集团) | China | Nucleating agents, PVC stabilisers, phenolic/epoxy resins | Valuation comparables; Shengquan is also an electronic-resin competitor |
PBAT | Kingfa Sci & Tech; Xinjiang Blue Ridge Tunhe; others | China | PBAT | Industry overcapacity; Ruifeng is subscale |
Electronic resins (Mituo) | Tongyu New Materials (同宇新材, 301630.SZ); Shengquan; Hongchang Electronic; Kolon; Nan Ya | China / Taiwan / Korea | CCL epoxy, PPO, BMI, hydrocarbon resins | Mituo is a small entrant (CNY 41M revenue in 2025) |
SBR binder | Zeon; JSR; domestic binder makers | Japan / China | Anode SBR | Ruifeng is pre-commercial |
Competitor Detail
| Metric | Ruifeng FY2025 |
|---|---|
Revenue | CNY 1,969M |
Revenue growth | −1.59% |
Gross margin | 14.57% |
Operating margin | 3.89% |
R&D intensity | 0.44% (S&P basis; CAS figure likely higher) |



